Azitra Soars 46% on EPS Revision; CRWD Jumps 19.6%
Stocks with the strongest post-revision gains include Azitra (AZTR), up 46.1% after its next-year EPS estimate was raised to 68.0% on August 21. CrowdStrike (CRWD) gained 19.6% following a record Q2 earnings beat and an upward EPS revision. Emergent BioSolutions (EBS) rose 16.9%, Xometry (XMTR) 15.8%, and Cypherpunk Technologies (CYPH) 12.5%, all driven by positive earnings estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| AZTR | Healthcare | 2026-08-21 | +8.4pp | +46.1% |
| CRWD | Technology | 2026-08-24 | N/A | +19.6% |
| EBS | Healthcare | 2026-08-21 | N/A | +16.9% |
| XMTR | Industrials | 2026-08-20 | N/A | +15.8% |
| CYPH | Healthcare | 2026-08-24 | +85.4pp | +12.5% |
Why did AZTR stock jump in August 2026?
AZTR jumped 46.1% from $0.13 to $0.19 after analysts raised its forward EPS growth estimate from 59.6% to 68.0% on August 21, signaling stronger expected profitability.
The revision was detected by the screener before any earnings news, suggesting the move was driven by analyst model updates rather than a specific catalyst. As a small-cap healthcare name, AZTR's price action likely reflects renewed investor appetite for speculative biotech plays following the revision. The stock's low absolute price amplifies percentage moves, but the EPS estimate shift was the primary trigger.
AZTR EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: AZTR
Why did AZTR stock jump in August 2026?
Azitra's stock surged 46.1% after analysts raised its forward EPS growth estimate from 59.6% to 68.0% on August 21, signaling improved profit outlook.
Is AZTR a buy after the rally?
With a 68% EPS growth estimate and no negative news, AZTR could be attractive, but investors should weigh high volatility and lack of recent earnings catalysts.
What is AZTR's EPS growth estimate?
Azitra's next-year EPS growth estimate stands at 68.0%, up from 59.6% after the August 21 revision.
Why did CRWD stock jump in August 2026?
CRWD jumped 19.6% from $190.68 to $227.96 after its next-year EPS growth estimate hit 26.5% and the company delivered record-breaking Q2 earnings on August 27.
Revenue rose 26% to $1.47 billion, beating estimates, while adjusted EPS of $0.31 also topped expectations. The raise in full-year guidance and a 51% surge in net new ARR reinforced the EPS revision, driving a 15% single-day spike. Cybersecurity demand, particularly for AI workload protection, continues to support the stock's upward momentum.
CRWD EPS revision history → · Screener snapshot from 2026-08-24 →
FAQ: CRWD
Why did CRWD stock jump in August 2026?
CrowdStrike jumped 19.6% after beating Q2 estimates and raising its outlook, with revenue up 26% to $1.47 billion and EPS growth expected at 26.5%.
Is CRWD a buy after the rally?
Given the strong earnings beat and raised guidance, CRWD remains a solid buy, though its valuation is stretched after the 20% surge.
What is CRWD's EPS growth estimate?
CrowdStrike's next-year EPS growth estimate is 26.5%, supported by a 25% increase in ARR to $5.84 billion.
Why did EBS stock jump in August 2026?
EBS climbed 16.9% from $5.08 to $5.94 after analysts set its next-year EPS growth estimate at an impressive 191.0% on August 21.
The screener flagged the revision before any earnings news, indicating the move was purely estimate-driven. As a healthcare company, EBS may be benefiting from improved pipeline confidence or cost control expectations. The high projected growth, if realized, could justify further upside, though investors should watch for upcoming catalysts.
EBS EPS revision history → · Screener snapshot from 2026-08-21 →
FAQ: EBS
Why did EBS stock jump in August 2026?
Emergent BioSolutions rose 16.9% after its next-year EPS growth estimate was set at 191.0% on August 21, signaling strong expected profit recovery.
Is EBS a buy after the rally?
With a 191% EPS growth estimate, EBS offers high upside potential, but the lack of news and small-cap volatility warrant caution.
What is EBS's EPS growth estimate?
EBS's next-year EPS growth estimate is 191.0%, reflecting a major anticipated earnings turnaround.
Why did XMTR stock jump in August 2026?
XMTR advanced 15.8% from $83.12 to $96.26 after its next-year EPS growth estimate reached 84.4% on August 20, triggering the screener.
The move occurred without any earnings news, pointing to analyst optimism about the company's growth trajectory in digital manufacturing. Strong industrial sector momentum and Xometry's AI-driven marketplace likely underpinned the estimate revision. The stock's gain suggests the market is rewarding companies with accelerating profit growth even in the absence of headlines.
XMTR EPS revision history → · Screener snapshot from 2026-08-20 →
FAQ: XMTR
Why did XMTR stock jump in August 2026?
Xometry rose 15.8% after analysts set its next-year EPS growth estimate at 84.4% on August 20, signaling strong expected profit acceleration.
Is XMTR a buy after the rally?
With an 84.4% EPS growth estimate and no negative catalysts, XMTR appears attractive, but investors should monitor execution.
What is XMTR's EPS growth estimate?
Xometry's next-year EPS growth estimate is 84.4%, reflecting expectations of rapid profit expansion.
Why did CYPH stock jump in August 2026?
CYPH rose 12.5% from $1.68 to $1.89 after analysts raised its forward EPS growth estimate from 254.6% to 340.0% on August 24, an 85.4pp upward revision.
The screener flagged the change, which occurred without any earnings news, suggesting analyst model updates drove the move. As a healthcare small-cap, CYPH's high growth estimate likely reflects optimism about a new product or trial. The spike aligns with broader momentum in biotech names with improving earnings outlooks.
CYPH EPS revision history → · Screener snapshot from 2026-08-24 →
FAQ: CYPH
Why did CYPH stock jump in August 2026?
Cypherpunk Technologies gained 12.5% after analysts raised its EPS growth estimate from 254.6% to 340.0% on August 24.
Is CYPH a buy after the rally?
With a 340% EPS growth estimate, CYPH offers significant upside, but the lack of news and small-cap risk require careful evaluation.
What is CYPH's EPS growth estimate?
CYPH's next-year EPS growth estimate is 340.0%, up from 254.6% after the August 24 revision.
Today's top performers, led by AZTR's 46% gain, show that EPS estimate revisions continue to be powerful catalysts, especially for smaller caps. The absence of major news for most stocks underscores how analyst model updates can drive price action, while CRWD's earnings beat highlights the reinforcing effect of fundamentals.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →